Key facts
- It has raised $3.4M; the latest was Early Stage VC in Jul 2025.
- Notable investors include Axon Partners Group, Bullnet Capital, CDTI Invierte.
- Status: Privately Held (backing).
- ·The complete investor list — 3 names
- ·Watchlist + deal alerts for Bioherent
- ·The full record, as it builds
Funding rounds
No funding rounds for Bioherent are on record yet — either the company hasn't raised institutional capital, or the raise hasn't surfaced in our sources.
About Bioherent
Developer of photonic biosensors for the diagnosis of drug allergies intended to revolutionize drug allergy tests. The company develops sensitive, in-vitro, low-cost medical diagnostic structures, helping healthcare professionals to diagnose and treat allergic diseases more efficiently.
- Sector
- Healthcare
- HQ
- Malaga, Spain
- Founded
- 2021
- Employees
- 14
- Website
- bioherent.com/
- Ownership
- Privately Held (backing)
Bioherent doesn't have a composite mark yet — a PA Mark is published once enough pricing inputs exist (trade prints, fund marks, round prices). The rest of the record below builds toward it.
Recorded secondary trades
No secondary trades in Bioherent shares have been recorded yet. When a print lands — third-party, direct report, or platform — it appears here with structure, source, and price.
Institutional fund marks
No SEC-registered fund has reported a fair-value mark on Bioherent in its N-PORT filings yet. We sweep new filings monthly.